Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) Invested Capital (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Invested Capital for 11 consecutive years, with -$126.2 million as the latest value for Q4 2025.

  • Quarterly Invested Capital fell 1755.92% to -$126.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$126.2 million through Dec 2025, down 1755.92% year-over-year, with the annual reading at -$126.2 million for FY2025, 1755.92% down from the prior year.
  • Invested Capital for Q4 2025 was -$126.2 million at Cartesian Therapeutics, down from -$35.8 million in the prior quarter.
  • The five-year high for Invested Capital was $102.3 million in Q4 2022, with the low at -$411.9 million in Q4 2023.
  • Average Invested Capital over 5 years is -$13.3 million, with a median of -$2.2 million recorded in 2021.
  • The sharpest move saw Invested Capital soared 4910.51% in 2022, then crashed 4866.49% in 2025.
  • Over 5 years, Invested Capital stood at $28.5 million in 2021, then soared by 259.19% to $102.3 million in 2022, then tumbled by 502.6% to -$411.9 million in 2023, then surged by 98.35% to -$6.8 million in 2024, then plummeted by 1755.92% to -$126.2 million in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at -$126.2 million, -$35.8 million, and -$2.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.